**Supplementary Table 1 Immunomodulatory and Related Medications for IBM**

|  |
| --- |
| **IBM-related Medications** |
| Prednisone, methotrexate, IVIG, azathioprine, cyclosporine, cyclophosphamide, rituximab, etanercept, infliximab, beta interferon-1a, abatacept, adalimumab, alemtuzumab and oxandrolone |

IBM: inclusion body myositis; IVIG: intravenous immunoglobulin

**Supplementary Table 2 Subgroup Analysis of Comorbidities among Patients without Immunosuppressant Medications Use**

|  | **IBM**  **Cohort** | | **Non-IBM**  **Cohort** | |  |
| --- | --- | --- | --- | --- | --- |
| **(N=198)** | | **(N=1,536)** | |  |
| **N** | **%** | **N** | **%** | **p-value\*** |
| **Comorbid Conditions** |  |  |  |  |  |
| Anemia | 56 | 28.28% | 92 | 5.99% | <0.0001 |
| Arthralgia | 30 | 15.15% | 48 | 3.13% | <0.0001 |
| Myocardial infarction | 19 | 9.60% | 35 | 2.28% | <0.0001 |
| Cataract | 1 | 0.51% | 25 | 1.63% | 0.2212 |
| Congestive heart failure | 25 | 12.63% | 59 | 3.84% | <0.0001 |
| Cerebrovascular disease | 26 | 13.13% | 47 | 3.06% | <0.0001 |
| Depression | 26 | 13.13% | 44 | 2.86% | <0.0001 |
| Dementia | 5 | 2.53% | 14 | 0.91% | 0.0401 |
| Dysphagia | 55 | 27.78% | 18 | 1.17% | <0.0001 |
| Rheumatic disease | 14 | 7.07% | 5 | 0.33% | <0.0001 |
| Peptic ulcer disease | 4 | 2.02% | 6 | 0.39% | 0.0044 |
| Mild liver disease | 8 | 4.04% | 9 | 0.59% | <0.0001 |
| Diabetes without chronic complication | 47 | 23.74% | 126 | 8.20% | <0.0001 |
| Diabetes with chronic complication | 17 | 8.59% | 15 | 0.98% | <0.0001 |
| Hemiplegia or paraplegia | 16 | 8.08% | 5 | 0.33% | <0.0001 |
| Renal disease | 8 | 4.04% | 67 | 4.36% | 0.8342 |
| Any malignancy, including lymphoma, leukemia, except malignant neoplasm of skin | 16 | 8.08% | 58 | 3.78% | 0.0048 |
| Moderate or severe liver disease | 0 | 0.00% | 4 | 0.26% | 0.4722 |
| Metastatic solid tumor | 3 | 1.52% | 8 | 0.52% | 0.0972 |
| AIDS/HIV | 1 | 0.51% | 1 | 0.07% | 0.0861 |
| Hyperlipidemia | 91 | 45.96% | 257 | 16.73% | <0.0001 |
| Hypertension | 130 | 65.66% | 305 | 19.86% | <0.0001 |
| Insomnia | 9 | 4.55% | 10 | 0.65% | <0.0001 |
| Fatigue | 35 | 17.68% | 43 | 2.80% | <0.0001 |
| Peripheral vascular disease | 19 | 9.60% | 42 | 2.73% | <0.0001 |
| Chronic pulmonary disease | 30 | 15.15% | 77 | 5.01% | <0.0001 |
| Pneumonia | 13 | 6.57% | 19 | 1.24% | <0.0001 |
| Aspiration Pneumonia | 10 | 5.05% | 3 | 0.20% | <0.0001 |
| Choking | 0 | 0.00% | 2 | 0.13% | 0.6114 |
| Accidental falls | 5 | 2.53% | 4 | 0.26% | <0.0001 |
| Osteoporosis | 24 | 12.12% | 38 | 2.47% | <0.0001 |
| Fibromyalgia | 43 | 21.72% | 10 | 0.65% | <0.0001 |
| Osteoarthritis | 28 | 14.14% | 75 | 4.88% | <0.0001 |
| Rheumatoid arthritis | 2 | 1.01% | 5 | 0.33% | 0.1528 |

\*p-value <0.05 is significant

IBM: inclusion body myositis